{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:29:12Z","timestamp":1791084552314,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Among patients diagnosed with schizophrenia, the presence of substance use poses an aggravating comorbidity, exerting a negative impact on the course of the disease, adherence to therapeutic regimens, treatment outcomes, duration of hospital stays, and the frequency of hospitalizations. The primary objective of the present study is to investigate the relationship between comorbid substance use disorders, antipsychotic treatment, and the length of stay in individuals hospitalized for treatment of schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of electronic health records spanning a 12-month period, specifically focusing on adult patients diagnosed with schizophrenia who were discharged from the University Hospital of Psychiatry Zurich between January and December 2019. We documented the number and types of diagnosed substance use disorder, the antipsychotic treatment, the length of stay, and the number of previous hospitalizations for each patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a third (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009328; 37.1%) of patients with schizophrenia had comorbid substance use with cannabis being the most frequent consumed substance. Patients with substance use (either single or multiple) were more frequently hospitalized; those with multiple substance use more frequently than those with a single substance use (\n                      <jats:italic>F<\/jats:italic>\n                      (2, 882)\u2009=\u200969.06;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). There were no differences regarding the rate of compulsory admission. Patients with no substance use had a lower HoNOS score at discharge (\n                      <jats:italic>F<\/jats:italic>\n                      (2, 882)\u2009=\u20094.06). Patients with multiple substance use had a shorter length of stay (\n                      <jats:italic>F<\/jats:italic>\n                      (2, 882)\u2009=\u20099.22;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), even after adjusting for duration of illness, previous hospitalizations, diagnosis, and antipsychotic treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with schizophrenia, comorbid single or multiple substance use has a relevant negative impact on treatment and thus on the course of disease. Substance use in patients with schizophrenia should therefore receive special attention in order to reduce re-hospitalization rates and improve the clinical outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-024-03447-3","type":"journal-article","created":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T20:01:34Z","timestamp":1717963294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Examining the impact of substance use on hospital length of stay in schizophrenia spectrum disorder: a retrospective analysis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-5655","authenticated-orcid":false,"given":"Achim","family":"Burrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan T.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias R.","family":"Spiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Homan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"4","key":"3447_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.addbeh.2011.11.039","volume":"37","author":"LK Thornton","year":"2012","unstructured":"Thornton LK, Baker AL, Lewin TJ, Kay-Lambkin FJ, Kavanagh D, Richmond R, Kelly B, Johnson MP. Reasons for substance use among people with mental disorders. Addict Behav. 2012;37(4):427\u201334.","journal-title":"Addict Behav"},{"issue":"1","key":"3447_CR2","first-page":"5","volume":"24","author":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","year":"2000","unstructured":"National Institute on Alcohol Abuse and Alcoholism (NIAAA). Health risks and benefits of alcohol consumption. Alcohol Res Health. 2000;24(1):5\u201311.","journal-title":"Alcohol Res Health"},{"issue":"1","key":"3447_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/NMD.0000000000000231","volume":"203","author":"HE Wu","year":"2015","unstructured":"Wu HE, Mohite S, Ngana I, Burns W, Shah N, Schneider L, Schmitz JM, Lane SD, Okusaga OO. Hospital length of stay in individuals with schizophrenia with and without cocaine-positive urine drug screens at hospital admission. J Nerv Ment Dis. 2015;203(1):33\u20136.","journal-title":"J Nerv Ment Dis"},{"key":"3447_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12913-015-1107-6","volume":"15","author":"R Jacobs","year":"2015","unstructured":"Jacobs R, Gutacker N, Mason A, Goddard M, Gravelle H, Kendrick T, Gilbody S. Determinants of hospital length of stay for people with serious mental illness in England and implications for payment systems: a regression analysis. BMC Health Serv Res. 2015;15:439.","journal-title":"BMC Health Serv Res"},{"issue":"1\u20133","key":"3447_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.schres.2011.04.011","volume":"130","author":"LM Schmidt","year":"2011","unstructured":"Schmidt LM, Hesse M, Lykke J. The impact of substance use disorders on the course of schizophrenia\u2014a 15-year follow-up study: dual diagnosis over 15 years. Schizophr Res. 2011;130(1\u20133):228\u201333.","journal-title":"Schizophr Res"},{"issue":"2","key":"3447_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.15288\/jsad.2019.80.230","volume":"80","author":"H Deng","year":"2019","unstructured":"Deng H, Desai PV, Mohite S, Okusaga OO, Zhang XY, Nielsen DA, Kosten TR. Hospital stay in synthetic cannabinoid users with bipolar disorder, schizophrenia, or other psychotic disorders compared with cannabis users. J Stud Alcohol Drugs. 2019;80(2):230\u20135.","journal-title":"J Stud Alcohol Drugs"},{"issue":"3\u20134","key":"3447_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/15504263.2016.1245457","volume":"12","author":"JM Johnson","year":"2016","unstructured":"Johnson JM, Wu CY, Winder GS, Casher MI, Marshall VD, Bostwick JR. The effects of cannabis on inpatient agitation, aggression, and length of stay. J Dual Diagn. 2016;12(3\u20134):244\u201351.","journal-title":"J Dual Diagn"},{"issue":"12","key":"3447_CR8","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1017\/S0033291714000191","volume":"44","author":"E Manrique-Garcia","year":"2014","unstructured":"Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med. 2014;44(12):2513\u201321.","journal-title":"Psychol Med"},{"issue":"3","key":"3447_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/15504263.2019.1609149","volume":"15","author":"S Florentin","year":"2019","unstructured":"Florentin S, Rosca P, Raskin S, Bdolah-Abram T, Neumark Y. Psychiatric hospitalizations of chronic psychotic disorder patients with and without dual diagnosis, Israel, 1963\u20132016. J Dual Diagn. 2019;15(3):130\u20139.","journal-title":"J Dual Diagn"},{"key":"3447_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1192\/bjp.bp.104.007237","volume":"188","author":"TR Barnes","year":"2006","unstructured":"Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237\u201342.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"3447_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/07067437221128477","volume":"68","author":"JP Loyal","year":"2023","unstructured":"Loyal JP, Lavergne MR, Shirmaleki M, Fischer B, Kaoser R, Makolewksi J, Small W. Trends in involuntary psychiatric hospitalization in British Columbia: descriptive analysis of population-based linked administrative data from 2008 to 2018. Can J Psychiatry. 2023;68(4):257\u201368.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"3447_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/schbul\/sbp135","volume":"37","author":"S Fazel","year":"2011","unstructured":"Fazel S, Yu R. Psychotic disorders and repeat offending: systematic review and meta-analysis. Schizophr Bull. 2011;37(4):800\u201310.","journal-title":"Schizophr Bull"},{"issue":"12","key":"3447_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00127-005-0964-4","volume":"40","author":"MT Compton","year":"2005","unstructured":"Compton MT, Weiss PS, West JC, Kaslow NJ. The associations between substance use disorders, schizophrenia-spectrum disorders, and axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol. 2005;40(12):939\u201346.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"3","key":"3447_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/jpm12030441","volume":"12","author":"S Reymann","year":"2022","unstructured":"Reymann S, Schoretsanitis G, Egger ST, Mohonko A, Kirschner M, Vetter S, Homan P, Seifritz E, Burrer A. Use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in Switzerland. J Pers Med. 2022;12(3):441.","journal-title":"J Pers Med"},{"issue":"11","key":"3447_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1192\/pb.18.11.690","volume":"18","author":"J Wing","year":"1994","unstructured":"Wing J, Curtis R, Beevor A. \u2018Health of the Nation\u2019: measuring mental health outcomes. Psychiatr Bull. 1994;18(11):690\u20131.","journal-title":"Psychiatr Bull"},{"issue":"12","key":"3447_CR16","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/0004867420963725","volume":"54","author":"ST Egger","year":"2020","unstructured":"Egger ST, Bobes J, Theodoridou A, Seifritz E, Vetter S. Assessing the severity of psychiatric disorders using the Health of the Nation Outcome Scales: an equipercentile linking analysis. Aust N Z J Psychiatry. 2020;54(12):1192\u20139.","journal-title":"Aust N Z J Psychiatry"},{"issue":"15","key":"3447_CR17","doi-asserted-by":"publisher","first-page":"e25206","DOI":"10.1097\/MD.0000000000025206","volume":"100","author":"E Chen","year":"2021","unstructured":"Chen E, Bazargan-Hejazi S, Ani C, Hindman D, Pan D, Ebrahim G, Shirazi A, Banta JE. Schizophrenia hospitalization in the US 2005\u20132014: examination of trends in demographics, length of stay, and cost. Medicine (Baltimore). 2021;100(15):e25206.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"3447_CR18","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1017\/S0033291722000794","volume":"53","author":"P Homan","year":"2022","unstructured":"Homan P, Schooler NR, Brunette MF, Rotondi A, Ben-Zeev D, Gottlieb JD, et al. Relapse prevention through health technology program reduces hospitalization in schizophrenia. Psychol Med. 2022;53(9):4114\u201320.","journal-title":"Psychol Med"},{"issue":"1\u20133","key":"3447_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.schres.2007.07.006","volume":"97","author":"B Lay","year":"2007","unstructured":"Lay B, Nordt C, R\u00f6ssler W. Trends in psychiatric hospitalisation of people with schizophrenia: a register-based investigation over the last three decades. Schizophr Res. 2007;97(1\u20133):68\u201378.","journal-title":"Schizophr Res"},{"issue":"3","key":"3447_CR20","first-page":"115","volume":"18","author":"AB Busch","year":"2015","unstructured":"Busch AB, Epstein AM, McGuire TG, Normand SL, Frank RG. Thirty-day hospital readmission for Medicaid enrollees with schizophrenia: the role of local health care systems. J Ment Health Policy Econ. 2015;18(3):115\u201324.","journal-title":"J Ment Health Policy Econ"},{"issue":"11","key":"3447_CR21","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1080\/10826084.2021.1949615","volume":"56","author":"SR Williams","year":"2021","unstructured":"Williams SR, Agapoff JRT, Jalan D, Hishinuma ES, Kida LE. Psychiatric hospitalization and length of stay differences in cannabis users and non-users with a primary discharge diagnosis of schizophrenia or schizoaffective disorder. Subst Use Misuse. 2021;56(11):1736\u20139.","journal-title":"Subst Use Misuse"},{"key":"3447_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"3447_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0447.2012.01911.x","volume":"127","author":"H J\u00f3nsd\u00f3ttir","year":"2013","unstructured":"J\u00f3nsd\u00f3ttir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, Vaskinn A, Friis S, Sundet K, Andreassen OA. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127(1):23\u201333.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"3447_CR24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12888-022-04022-x","volume":"22","author":"D Lin","year":"2022","unstructured":"Lin D, Kim H, Wada K, Aboumrad M, Powell E, Zwain G, Benson C, Near AM. Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database: societal burden of schizophrenia among US veterans. BMC Psychiatry. 2022;22(1):458.","journal-title":"BMC Psychiatry"},{"key":"3447_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.schres.2017.04.016","volume":"194","author":"JY Khokhar","year":"2018","unstructured":"Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr Res. 2018;194:78\u201385.","journal-title":"Schizophr Res"},{"key":"3447_CR26","doi-asserted-by":"publisher","first-page":"109926","DOI":"10.1016\/j.pnpbp.2020.109926","volume":"101","author":"M Kirschner","year":"2020","unstructured":"Kirschner M, Rabinowitz A, Singer N, Dagher A. From apathy to addiction: insights from neurology and psychiatry. Prog Neuropsychopharmacol Biol Psychiatry. 2020;101:109926.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"3447_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jclinepi.2010.04.023","volume":"64","author":"HM Smeets","year":"2011","unstructured":"Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol. 2011;64(4):424\u201330.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03447-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T20:02:22Z","timestamp":1717963342000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03447-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate.The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Canton of Zurich (BASEC-Nr. Req-2021\u201300376, approval date: 8 March 2021 and 26 October 2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB has received speaking and travel fees from Recordati, Schwabe, and Lundbeck. PH has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen, Boehringer Ingelheim, and Neurolite outside of this work. ES has received in the last 3\u00a0years honoraria and grants for advice and educational lectures from Lundbeck Switzerland, Schwabe Switzerland and Germany, Janssen Switzerland, Otsuka Pharmaceutical Switzerland, Mepha Pharma Switzerland, Recordati Switzerland, Sunovion Pharma UK, and Angelini. The other authors declare that they have no competing interests in this section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}